- Location advantages
- Research & development
€ 600 million for Austria as a business location
The research and business location of Austria will receive funding of € 600 million up until the year 2026. In the period 2023 to 2026, € 550 million will be made available for the transformation and € 50 million for semiconductor production.
Funded will be provided in three areas, namely research and technology development, business location and investment promotion and qualifications, according to Federal Minister of Labour and Economy Martin Kocher. In particular, the measures are designed to appeal to industrial flagship companies, but funding is also open to all company sizes. Austria has also committed an additional € 600 million up to 2026 to promote environmental protection measures. This funding should serve to support the transition to a sustainable economy based on renewable energies which is digitalised in all sectors.
Furthermore, the Austrian government also promotes the semiconductor segment through a broad range of funding schemes. Austria is one of the most important locations for microelectronics within the EU. The “Lab2Fab” funding programme will be relaunched and financed by the Austrian Future Fund. A total of € 12 million will be made available for this purpose. The objective of the new funding initiative is to support the Austrian semiconductor industry and related sectors in implementing multi-year projects involving research and development, testing, upscaling and building up industrial production capacities for semiconductor products.
- Continue reading and learn more about funding programmes in Austria!
Attractive research and innovation location27. February 2024
ABA’s INVEST in AUSTRIA business area coordinated the handling of 1,354 inquiries on the part of international companies in 2023 and ended up overseeing 496 ongoing business location and expansion projects.
Novartis invests about € 500 million in its Austrian facilities27. February 2024
The investment strengthens the Tyrolean Kundl/Schaftenau campus as a leading biotech location in Europe and helps accelerate the continuous supply of biopharmaceuticals from Austria. The Schaftenau plant is scheduled to be fully operational in the summer of 2024, whereas the Kundl facility will be operational in the autumn of 2025, creating 350 new high-skilled jobs on campus.